Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Update

Sunshine Biopharma, Inc. (NASDAQ:SBFM) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 113,100 shares, a growth of 78.1% from the February 28th total of 63,500 shares. Based on an average daily trading volume, of 78,400 shares, the days-to-cover ratio is currently 1.4 days. Approximately 4.2% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Aegis restated a “buy” rating and set a $15.00 price objective on shares of Sunshine Biopharma in a research note on Thursday, December 5th.

Hedge Funds Weigh In On Sunshine Biopharma

An institutional investor recently bought a new position in Sunshine Biopharma stock. Connective Capital Management LLC acquired a new stake in Sunshine Biopharma, Inc. (NASDAQ:SBFM) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 11,345 shares of the company’s stock, valued at approximately $34,000. Connective Capital Management LLC owned about 0.93% of Sunshine Biopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 41.98% of the company’s stock.

Sunshine Biopharma Price Performance

SBFM stock traded down $0.10 during midday trading on Friday, reaching $2.00. The company had a trading volume of 22,287 shares, compared to its average volume of 280,942. Sunshine Biopharma has a 1-year low of $1.90 and a 1-year high of $265.00. The stock has a 50 day moving average price of $2.43 and a 200-day moving average price of $2.73. The company has a market capitalization of $2.45 million, a price-to-earnings ratio of -0.01 and a beta of 1.35.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.